CTSO Earnings & Financial Statements
Cytosorbents Corporation
$3.09
$0.00(0.00%)
38
Overall
60
Value
9
Tech
47
Quality
Market Cap
$9.74M
Volume
9.24K
52W Range
$3.59 - $19.71
Target Price
$106.25
CTSO earnings and financial statements: Cytosorbents Corporation's income statement, balance sheet and cash flow statement, annual and quarterly.
CTSO Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $37.06M | $35.59M | $31.08M | $29.36M | $43.17M |
| Cost of revenue | $10.57M | $10.71M | $9.13M | $13.96M | $11.05M |
| Operating income | -$14.75M | -$16.45M | -$31.95M | -$31.52M | -$22.74M |
| EBITDA | -$3.67M | -$19.18M | -$27.88M | -$30.39M | -$21.62M |
| Net income | -$8.20M | -$20.72M | -$29.25M | -$32.81M | -$24.56M |
| EPS (diluted) | $-0.13 | $-0.38 | $-0.64 | $-0.75 | $-0.57 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $44.18M | $47.37M | $52.96M | $63.23M | $89.52M |
| Total liabilities | $38.28M | $36.27M | $29.48M | $27.86M | $26.94M |
| Shareholders’ equity | $5.90M | $11.11M | $23.48M | $35.37M | $62.58M |
| Cash and equivalents | $6.25M | $3.28M | $14.13M | $22.14M | $52.14M |
| Long-term debt | $28.57M | $26.44M | $15.44M | $18.14M | $13.25M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$12.38M | -$14.43M | -$21.66M | -$28.23M | -$14.01M |
| Capital expenditure | -$415.0K | -$669.0K | -$936.2K | -$6.46M | -$4.28M |
| Free cash flow | -$12.87M | -$15.10M | -$22.59M | -$34.69M | -$18.29M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CTSO | $3.09 | 0% | 9.24K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Cytosorbents Corporation Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW